Pyxis Oncology (PYXS) Revenue (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Revenue of $11.0 million for Q4 2025, up 291.42% quarter-over-quarter from $2.8 million in Q2 2025.

Pyxis Oncology (PYXS) Revenue (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Revenue for 2 consecutive years, with $11.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Revenue changed N/A year-over-year to $11.0 million; the TTM figure through Dec 2025 stood at $13.9 million (down 14.17% YoY), while the FY2025 annual figure was $13.9 million, down 14.17% from the prior year.
Revenue climbed to $11.0 million in Q4 2025 per PYXS's latest filing, from $2.8 million in the prior quarter.
Across five years, Revenue topped out at $16.1 million in Q1 2024 and bottomed at $2.8 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-	-

Download Data